Curanex Pharmaceuticals Inc. announced the full exercise of the over-allotment option by Dominari Securities LLC, the lead underwriter for its IPO.
562,500 additional shares of common stock were purchased at the IPO price of $4.00 per share, raising an extra $2,250,000 in gross proceeds.
The total gross proceeds from the offering reached $17,250,000 after the sale of 4,312,500 shares in the IPO.
Over-Allotment Option Exercised
Dominari Securities LLC exercised the over-allotment option in full, purchasing 562,500 additional shares at $4.00 per share.
Total Gross Proceeds
The Company raised a total of $17,250,000 in gross proceeds through the issuance of 4,312,500 shares of common stock.
Underwriters and Counsel
Dominari Securities LLC, Pacific Century Securities LLC, and Revere Securities LLC acted as underwriters with legal counsel provided by The Crone Law Group, P.C. and Sichenzia Ross Ference Carmel LLP.
- The full exercise of the over-allotment option indicates strong investor demand and confidence in Curanex Pharmaceuticals Inc.
- The additional proceeds will support the Company's continued research and development efforts in discovering botanical drugs for inflammatory diseases.
Curanex Pharmaceuticals Inc.'s successful over-allotment option exercise demonstrates positive market reception and provides additional funding for its botanical drug development.